Indian Pharma Market Posts Moderate Revenue Growth In September
The Indian pharmaceutical market witnessed moderate growth in September, with sales rising by 5.3% compared to the previous year. This growth was slightly lower than the 6.3% increase recorded in August but, higher than the 2.1% growth seen a year ago.
Overall, the growth in September was attributed to a 5.3% rise in prices and a 2.4% boost from new product launches. However, volume growth remained weak and witnessed a 2.4% drop.
In the period between January and September in 2024, the Indian pharmaceutical market grew by an average of 7.6%, but volume growth stayed negative at 0.9%.
Specific therapy areas like cardiac (9.5%), dermatology (9.7%), gastro (5.7%), and CNS (6.3%) outperformed the overall market growth in September.
Krishnanath Munde, associate director at India Ratings and Research told NDTV Profit, “Ind-Ra expect IPM growth to be at 8–9% YoY for FY25 against 6.5% YoY in FY24, and 9.9% YoY growth in FY23.”
Key Highlights
Volume growth declined 2.4%. It had declined 5.6% in September 2023.
In September this year, prices rose 5.3% compared to a 4.8% rise over the same period last year.
New launches increased 2.4%, as against 2.9% in Sept. 2023.
MAT Performance
The moving annual total—or the 12-month rolling sales of overall pharma products—increased 8.5% in September.
Outperformers: Leading The Pack
Several pharmaceutical companies have outpaced the Indian pharmaceutical market, with impressive year-on-year growth.
Indoco Remedies Ltd. emerged as a standout with an 11.5% growth, followed by Cipla Ltd. that posted a strong 10.8%. Torrent Pharmaceuticals Ltd. witnessed a 9.7% increase, closely trailing Sun Pharmaceutical Industries Ltd. with an 8.6% growth.
Other companies that performed above industry standards include Alkem Laboratories Ltd. (8.1%), GlaxoSmithKline Pharmaceuticals Ltd. (8%), and Ajanta Pharma Ltd. (7.8%).
Notable mentions like Eris Lifesciences Ltd. (7.1%), Mankind Pharma Ltd. (6.9%), IPCA Laboratories Ltd. (6.9%), and Zydus Lifesciences Ltd. (6.3%) also saw robust gains, showcasing their ability to thrive in a competitive market. Even Emcure Pharmaceuticals Ltd. registered a solid 5.8%, highlighting the group's success.
In Line With Market
Some companies performed consistently with the overall market growth.
Glenmark Pharmaceuticals Ltd. achieved 5.2% YoY growth, while JB Chemicals & Pharmaceuticals Ltd. followed closely with a 5.4% increase. These companies managed to maintain a steady growth, keeping pace with the overall trends in the Indian pharmaceutical market.
Underperformers: Falling Behind The Market
Some companies underperformed compared to the market.
Dr Reddy's Laboratories Ltd. reported a modest 3.4% growth, while Abbott India Ltd. and FDC Ltd. posted similar results with 3.3% and 3.2% YoY growth, respectively.
Lupin Ltd. lagged further behind at 2.7%, while Sanofi India Ltd. grew by 5%, just shy of outperforming.
Unfortunately, Pfizer Ltd. and Alembic Pharmaceuticals Ltd. witnessed declines in growth, reporting -5.7% and -6% respectively, marking a challenging year for these companies.
-
We May Need Another Tukaram Mundhe To Fight Air Pollution | The Reason Why
Developers may install basic measures such as sprinklers and green nets, resume work, and continue violating rules when this equipment stops working.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.